Intralesional Vit. D as a cost effective modality for multiple warts: Case report
The cost effective approach for developing country ?
DOI:
https://doi.org/10.66344/jpad.v33i3.2290Keywords:
wart, immunotherapy, vitdAbstract
All modalities of treatment for warts can be painful and may be associated with scarring and frequent recurrences. In addition, destructive modalities are not suitable for the treatment of multiple and refractory warts as they clear only treated lesions and not the distant ones. Hence, to overcome these shortcomings, immunotherapy is being tried widely for the treatment of warts over the last few years. It acts on the basic principle of enhancing cell-mediated immunity for the clearance of warts. Various antigens have been tried including measles, mumps, rubella (MMR); tuberculin purified protein derivative (PPD); Mycobacterium w vaccine and Candida antigen. However the cost of these treatment modalities is high. In a developing country, the affordability of the treatment plays a very important role in managing the patient with the disease. vitamin D comes up as one of the most affordable options for immunotherapy of the same.
References
1. Sterling JC, Handfield-Jones S, Hudson PM. British Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144:4–11
2. Gibbs S, Harvey I, Sterling J, Stark R. Local treatments for cutaneous warts: Systematic review. BMJ. 2002;325:461.
3. Savant SS, Gore D. Electrosurgery. In: Savant SS, Shah RA, Gore D, editors. Textbook and Atlas of Dermatosurgery and Cosmetology. Mumbai: ASCAD; 2005:305–14.
4. Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol. 1995;132:433–6.
5. Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: A preliminary report. Lasers Surg Med. 1993;13:127–37.
6. Gonçalves MA, Donadi EA. Immune cellular response to HPV: Current concepts. Braz J Infect Dis. 2004;8:1–9.
7. Nofal A, Nofal E. Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24:1166–70.
8. Shaheen MA, Salem SA, Fouad DA, El-Fatah AA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther. 2015;28:194–200.
9. Garg S, Baveja S. Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine. J Cutan Aesthet Surg. 2014;7:203–8.
10. Majid I, Imran S. Immunotherapy with intralesional Candida albicans antigen in resistant or recurrent warts: A study. Indian J Dermatol. 2013;58:360–5.
11. Rind T, Oiso N, Kawada A. Successful treatment of anogenital wart with a topical vitamin D(3) Derivative in an infant. Case Rep Dermatol. 2010;2:46–49.
12. Imagawa I, Suzuki H. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007;34:264–6.
13. Aktas H, Ergin C, Demir B, Ekiz Ö. Intralesional vitamin D injection may be an effective treatment option for warts. J Cutan Med Surg. 2016;20:118–22.
14. Shalaby ME, Hasan MS, Elshorbagy MS, Abo Raya AR, Elsaie ML. Diagnostic and therapeutic implications of vitamin D deficiency in patients with warts: A case-controlled study. J Cosmet Dermatol. 2022;21(3):1135-42. doi: 10.1111/jocd.14156. Epub 2021 Apr 25. PMID: 33860625.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Dennis Henry, Daniel Henry
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
